Scheduling of taxanes: A review

Current Clinical Pharmacology

Volumn 5, Issue 3, 2010, Pages 226-231

  Woodward, Emma J ^a   Twelves, Chris ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Efficacy; Nab paclitaxel; Scheduling; Taxanes; Toxicity

Indexed keywords

ALBUMIN; BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; NANOPARTICLE; PACLITAXEL; TRASTUZUMAB;

ADJUVANT THERAPY; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG TOLERABILITY; EDEMA; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HUMAN; HYPERSENSITIVITY REACTION; INFUSION RATE; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ALBUMINS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEOPLASMS; PACLITAXEL; TAXOIDS;

EID: 78649301474     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488410791498725     Document Type: Article

References (47)

1. Wilson L, Miller HP, Farrell KW, Snyder KB, Thompson WC, Purich DL. Taxol stabilization of microtubules in vitro: dynamics of tubulin addition and loss at opposite microtubule ends. Biochemistry 1985; 24(19): 5254-62.
2. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996; 56(9): 2112-5.
3. Gianni L, Kearns CM, Giani A, et al, Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans, J Clin Oncol 1995;13(1):180-90.
4. Georgiadis MS RE, Johnson BE. Prolonging the exposure of human lung cancer cell lines to paclitaxel improves the cytotoxicity. Proc Am Assoc Cancer Res 1994; 35: 341.
5. Grem JL, Tutsch KD, Simon KJ, et al. Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep 1987; 71(12): 1179-84.
6. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 1987; 71(12): 1171-7.
7. Eisenhauer E, ten Bokkel Huinink W, Swenerton K, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12(12): 2654-66.
8. Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15(1): 187-92.
9. Seidman A, Hudis C, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16(10): 3353-61.
10. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 19(22): 4216-23.
11. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and leukemia Group B protocol 9840. J Clin Oncol 2008; 26(10): 1642-9.
12. Verrill MW, Lee J, Cameron DA, et al, Anglo-Celtic IV: First results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC), J Clin Oncol (Meeting Abstracts) 2007;25(18 suppl):LBA1005.
13. Belani CP, Dakhil S, Waterhouse DM, et al. Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Ann Oncol 2007; 18(1): 110-5.
14. Socinski MA, Ivanova A, Bakri K, et al. A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol 2006; 17(1): 104-9.
15. Belani CP, Ramalingam S, Perry MC, et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 2008; 26(3): 468-73.
16. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374(9698): 1331-8.
17. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21(8): 1431-9.
18. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358(16): 1663-71.
19. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005; 23(25): 5983-92.
20. Bissery M-C, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental Antitumor Activity of Taxotere (RP 56976, NSC 628503), a Taxol Analogue. Cancer Res 1991; 51(18): 4845-52.
21. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16(1): 187-96.
22. Cortes J, Pazdur R. Docetaxel. J Clin Oncol 1995; 13(10): 2643-55.
23. Gervais R, Ducolone A, Breton J-L, et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2005; 16(1): 90-6.
24. Camps C, Massuti B, Jimenez A, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 2006; 17(3): 467-72.
25. Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005; 23(33): 8389-95.
26. Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004; 91(12): 1996-2004.
27. Di Maio M, Perrone F, Chiodini P, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2007; 25(11): 1377-82.
28. Lai C-L, Tsai C-M, Chiu C-H, et al. Phase II Randomized Trial of Tri-weekly Versus Days 1 and 8 Weekly Docetaxel as a Second-line Treatment of Advanced Non-small Cell Lung Cancer. Jpn J Clin Oncol 2005; 35(12): 700-6.
29. Tabernero J, Climent MA, Lluch A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004; 15(9): 1358-65.
30. Rivera E, Mejia JA, Arun BK, et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer, Cancer 2008;112(7):1455-61.
31. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11): 783-92.
32. Marty M, Cognetti F, Maraninchi D, et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-Positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23(19): 4265-74.
33. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19(10): 2587-95.
34. Leyland-Jones B, Gelmon K, Ayoub JP, et al, Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel, J Clin Oncol 2003;21(21):3965-71.
35. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357(26): 2666-76.
36. Miles D, Chan A, Romieu G, et al, Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO, J Clin Oncol (Meeting Abstracts) 2008;26(15_suppl):LBA1011
37. Seidman AD. Will Weekly Work? Seems to Be So. J Clin Oncol 2005; 23(25): 5873-4.
38. Pasquier E, Honore S, Pourroy B, et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005; 65(6): 2433-40.
39. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001; 19(4): 1195-206.
40. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27(22): 3611-9.
41. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47(9): 2486-93.
42. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987; 5(8): 1232-9.
43. Wilson W, Berg S, Bryant G, et al. Paclitaxel in doxorubicinrefractory or mitoxantronerefractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12(8): 1621-9.
44. Seidman AD, Hochhauser D, Gollub M, et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996; 14(6): 1877-84.
45. Soulie P, Trandafir L, Taamma A, et al. Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer. Anticancer Drugs 1997; 8(8): 763-6.
46. Shade RJ, Pisters KM, Huber MH, et al. Phase I study of paclitaxel administered by ten-day continuous infusion. Invest New Drugs 1998; 16(3): 237-43.
47. Riseberg D, Cowan K, Zujewski J, et al. Phase I study of a 14-day paclitaxel infusion in patients with advanced malignancies, Proc Am Soc Clin Oncol 1995; 14: 1576.